Pharmaceutical

Kyowa Kirin gets grant for monoclonal antibody inhibiting ccr1 activation by ccl15

Discover the groundbreaking patent by Kyowa Kirin Co Ltd for a monoclonal antibody targeting CCR1, inhibiting its activation by CCL15. Explore the therapeutic and diagnostic potential for CCR1-related diseases.

Apr 11, 2024 - 00:00
Discover the groundbreaking patent by Kyowa Kirin Co Ltd for a monoclonal antibody targeting CCR1, inhibiting its activation by CCL15. Explore the therapeutic and diagnostic potential for CCR1-related diseases.
Read the original article

Tags:

Previous Article

ADMA Biologics gets grant for treatment of upper respiratory tract infection wit...

Next Article

Dynamic-EC: An efficient dynamic erasure coding method for permissioned blockcha...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sterilisation Solutions, Equipment and Services for the Pharmaceutical Industry

Sterilisation Solutions, Equipment and Services for the...

Oct 2, 2024

STAT+: Biotech executive nominated to Biogen board is mother of director’s child, records show

STAT+: Biotech executive nominated to Biogen board is m...

Jun 14, 2023

Opinion: Sobering centers offer a safe place to recover from intoxication. Every community should have one

Opinion: Sobering centers offer a safe place to recover...

Dec 13, 2023